Sitagliptin

Sitagliptin is a pyrazine-derived dipeptidyl-peptidase IV inhibitor and hypoglycemic agent that is used in conjunction with diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus. The effect of this medication leads to glucose dependent increases in insulin and decreases in glucagon to improve control of blood sugar. Modulates the levels of the incretin hormones glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide (GIP).

General

Type : Drug,Piperidine,Gliptin,Triazol,Trifluoro

Chemical_Nomenclature : (3R)-3-amino-1-[3-(trifluoromethyl)-6,8-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5-trifluorophenyl)butan-1-one

Canonical SMILES : C1CN2C(=NN=C2C(F)(F)F)CN1C(=O)CC(CC3=CC(=C(C=C3F)F)F)N

InChI : InChI=1S\/C16H15F6N5O\/c17-10-6-12(19)11(18)4-8(10)3-9(23)5-14(28)26-1-2-27-13(7-26)24-25-15(27)16(20,21)22\/h4,6,9H,1-3,5,7,23H2\/t9-\/m1\/s1

InChIKey : MFFMDFFZMYYVKS-SECBINFHSA-N

Other name(s) : Januvia,Xelevia,MK-0431,MK0431,Sitagliptan,715,DB01261,Cetagliptin,CHEBI:40237,CHEMBL1422,SCHEMBL17783


MW : 407.31

Formula : C16H15F6N5O

CAS_number : 486460-32-6

PubChem : 4369359

UniChem : MFFMDFFZMYYVKS-SECBINFHSA-N

IUPHAR : 6286

Wikipedia : Sitagliptin

Target

Families : Sitagliptin ligand of proteins in family: DPP4N_Peptidase_S9

Stucture :

Protein : human-DPP4 || bactn-BT4193

References (88)

Title : Antidiabetic drug sitagliptin blocks cyclophosphamide cerebral neurotoxicity by activating Nrf2 and suppressing redox cycle imbalance, inflammatory iNOS\/NO\/NF-B response and caspase-3\/Bax activation in rats - Famurewa_2023_Int.Immunopharmacol_116_109816
Author(s) : Famurewa AC , Asogwa NT , Ezea SC
Ref : Int Immunopharmacol , 116 :109816 , 2023
Abstract : Famurewa_2023_Int.Immunopharmacol_116_109816
ESTHER : Famurewa_2023_Int.Immunopharmacol_116_109816
PubMedSearch : Famurewa_2023_Int.Immunopharmacol_116_109816
PubMedID: 36774854

Title : Targeting DPP4-RBD interactions by sitagliptin and linagliptin delivers a potential host-directed therapy against pan-SARS-CoV-2 infections - Mani_2023_Int.J.Biol.Macromol_245_125444
Author(s) : Mani S , Kaur A , Jakhar K , Kumari G , Sonar S , Kumar A , Das S , Kumar S , Kumar V , Kundu R , Pandey AK , Singh UP , Majumdar T
Ref : Int J Biol Macromol , 245 :125444 , 2023
Abstract : Mani_2023_Int.J.Biol.Macromol_245_125444
ESTHER : Mani_2023_Int.J.Biol.Macromol_245_125444
PubMedSearch : Mani_2023_Int.J.Biol.Macromol_245_125444
PubMedID: 37385308
Gene_locus related to this paper: human-DPP4

Title : Sitagliptin attenuates neuronal apoptosis via inhibiting the endoplasmic reticulum stress after acute spinal cord injury - Tang_2023_Hum.Exp.Toxicol_42_9603271231168761
Author(s) : Tang C , Xu T , Dai M , Zhong X , Shen G , Liu L
Ref : Hum Exp Toxicol , 42 :9603271231168761 , 2023
Abstract : Tang_2023_Hum.Exp.Toxicol_42_9603271231168761
ESTHER : Tang_2023_Hum.Exp.Toxicol_42_9603271231168761
PubMedSearch : Tang_2023_Hum.Exp.Toxicol_42_9603271231168761
PubMedID: 36977492

Title : Sitagliptin Extends Lifespan of Caenorhabditis elegans by Inhibiting IIS and Activating DR-like Signaling Pathways - Ye_2023_Gerontology__
Author(s) : Ye Q , Li Y , Wang C , Zheng J , Qiao J , Yang J , Wan QL
Ref : Gerontology , : , 2023
Abstract : Ye_2023_Gerontology__
ESTHER : Ye_2023_Gerontology__
PubMedSearch : Ye_2023_Gerontology__
PubMedID: 37952525

Title : Mechanism of molecular interaction of sitagliptin with human DPP(4) enzyme - New Insights - Gonzatti_2023_Adv.Med.Sci_68_402
Author(s) : Gonzatti MB , Junior JEM , Rocha AJ , de Oliveira JS , Evangelista AJJ , Fonseca FMP , Ceccatto VM , de Oliveira AC , da Cruz Freire JE
Ref : Adv Med Sci , 68 :402 , 2023
Abstract : Gonzatti_2023_Adv.Med.Sci_68_402
ESTHER : Gonzatti_2023_Adv.Med.Sci_68_402
PubMedSearch : Gonzatti_2023_Adv.Med.Sci_68_402
PubMedID: 37837799

Title : Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Exhibits Antioxidant Mechanism for Abrogation of Cyclophosphamide-Induced Cardiac Damage and Oxidative Hepatorenal Toxicity in Rats - Famurewa_2022_Drug.Res.(Stuttg)__
Author(s) : Famurewa AC , Aja PM , Medewase JO , Abi I , Ogbonna OC , Ofor CC , Nwonuma CO , Asogwa NT , Erejuwa OO
Ref : Drug Res (Stuttg) , : , 2022
Abstract : Famurewa_2022_Drug.Res.(Stuttg)__
ESTHER : Famurewa_2022_Drug.Res.(Stuttg)__
PubMedSearch : Famurewa_2022_Drug.Res.(Stuttg)__
PubMedID: 35772725

Title : Evaluation of the anti-diabetic drug sitagliptin as a novel attenuate to SARS-CoV-2 evidence-based in silico: molecular docking and molecular dynamics - da Cruz Freire_2022_3.Biotech_12_344
Author(s) : da Cruz Freire JE , Jnior JEM , Pinheiro DP , da Cruz Paiva Lima GE , do Amaral CL , Veras VR , Madeira MP , Freire EBL , Ozrio RG , Fernandes VO , Montenegro A , Montenegro RC , Colares JKB , Jnior RMM
Ref : 3 Biotech , 12 :344 , 2022
Abstract : da Cruz Freire_2022_3.Biotech_12_344
ESTHER : da Cruz Freire_2022_3.Biotech_12_344
PubMedSearch : da Cruz Freire_2022_3.Biotech_12_344
PubMedID: 36382241

Title : A Rare Case Report of Sitagliptin-Induced Angioedema - Sharma_2022_Cureus_14_e30077
Author(s) : Sharma NR , Sharma B , Lamichhane S , Pokhrel M , Shrestha P
Ref : Cureus , 14 :e30077 , 2022
Abstract : Sharma_2022_Cureus_14_e30077
ESTHER : Sharma_2022_Cureus_14_e30077
PubMedSearch : Sharma_2022_Cureus_14_e30077
PubMedID: 36381841

Title : Sitagliptin Alleviates Radiation-Induced Intestinal Injury by Activating NRF2-Antioxidant Axis, Mitigating NLRP3 Inf--lammasome Activation, and Reversing Gut Microbiota Disorder - Huang_2022_Oxid.Med.Cell.Longev_2022_2586305
Author(s) : Huang S , Huang Y , Lin W , Wang L , Yang Y , Li P , Xiao L , Chen Y , Chu Q , Yuan X
Ref : Oxid Med Cell Longev , 2022 :2586305 , 2022
Abstract : Huang_2022_Oxid.Med.Cell.Longev_2022_2586305
ESTHER : Huang_2022_Oxid.Med.Cell.Longev_2022_2586305
PubMedSearch : Huang_2022_Oxid.Med.Cell.Longev_2022_2586305
PubMedID: 35620578

Title : Sitagliptin: a potential drug for the treatment of COVID-19? - Bardaweel_2021_Acta.Pharm_71_175
Author(s) : Bardaweel SK , Hajjo R , Sabbah DA
Ref : Acta Pharm , 71 :175 , 2021
Abstract : Bardaweel_2021_Acta.Pharm_71_175
ESTHER : Bardaweel_2021_Acta.Pharm_71_175
PubMedSearch : Bardaweel_2021_Acta.Pharm_71_175
PubMedID: 33151168

Title : Promoter Engineering-mediated Tuning of Esterase and Transaminase Expression for the Chemoenzymatic Synthesis of Sitagliptin Phosphate at the kilogram-scale - Khobragade_2021_Biotechnol.Bioeng__
Author(s) : Khobragade TP , Yu S , Jung H , Patil MD , Sarak S , Pagar AD , Jeon H , Lee S , Giri P , Kim GH , Cho SS , Park SH , Park HJ , Kang HM , Lee SR , Lee MS , Kim JH , Choi IS , Yun H
Ref : Biotechnol Bioeng , : , 2021
Abstract : Khobragade_2021_Biotechnol.Bioeng__
ESTHER : Khobragade_2021_Biotechnol.Bioeng__
PubMedSearch : Khobragade_2021_Biotechnol.Bioeng__
PubMedID: 33990942

Title : Combined use of GABA and sitagliptin promotes human beta-cell proliferation and reduces apoptosis - Liu_2021_J.Endocrinol_248_133
Author(s) : Liu W , Lau HK , Son DO , Jin T , Yang Y , Zhang Z , Li Y , Prud'homme GJ , Wang Q
Ref : J Endocrinol , 248 :133 , 2021
Abstract : Liu_2021_J.Endocrinol_248_133
ESTHER : Liu_2021_J.Endocrinol_248_133
PubMedSearch : Liu_2021_J.Endocrinol_248_133
PubMedID: 33258801

Title : Sitagliptin Modulates the Response of Ovarian Cancer Cells to Chemotherapeutic Agents - Kosowska_2020_Int.J.Mol.Sci_21_
Author(s) : Kosowska A , Garczorz W , Klych-Ratuszny A , Aghdam MRF , Kimsa-Furdzik M , Simka-Lampa K , Francuz T
Ref : Int J Mol Sci , 21 : , 2020
Abstract : Kosowska_2020_Int.J.Mol.Sci_21_
ESTHER : Kosowska_2020_Int.J.Mol.Sci_21_
PubMedSearch : Kosowska_2020_Int.J.Mol.Sci_21_
PubMedID: 33256016

Title : Higher-Dose Sitagliptin and the Risk of Congestive Heart Failure in Older Adults with CKD - Muanda_2020_Clin.J.Am.Soc.Nephrol_15_1728
Author(s) : Muanda FT , Weir MA , Bathini L , Clemens KK , Perkovic V , Sood MM , McArthur E , Sontrop JM , Kim RB , Garg AX
Ref : Clin J Am Soc Nephrol , 15 :1728 , 2020
Abstract : Muanda_2020_Clin.J.Am.Soc.Nephrol_15_1728
ESTHER : Muanda_2020_Clin.J.Am.Soc.Nephrol_15_1728
PubMedSearch : Muanda_2020_Clin.J.Am.Soc.Nephrol_15_1728
PubMedID: 33239410

Title : Effect of Anagliptin and Sitagliptin in Type 2 Diabetic Patients with Dyslipidemia and Cardiovascular Risk: What Is the Real REASON Behind It? -
Author(s) : Jonnalagadda VG , Char HP , Ankana PK
Ref : Cardiovasc Drugs Ther , 32 :311 , 2018
PubMedID: 29516206

Title : Saxagliptin but Not Sitagliptin Inhibits CaMKII and PKC via DPP9 Inhibition in Cardiomyocytes - Koyani_2018_Front.Physiol_9_1622
Author(s) : Koyani CN , Trummer C , Shrestha N , Scheruebel S , Bourgeois B , Plastira I , Kickmaier S , Sourij H , Rainer PP , Madl T , Sattler W , Pelzmann B , Malle E , von Lewinski D
Ref : Front Physiol , 9 :1622 , 2018
Abstract : Koyani_2018_Front.Physiol_9_1622
ESTHER : Koyani_2018_Front.Physiol_9_1622
PubMedSearch : Koyani_2018_Front.Physiol_9_1622
PubMedID: 30487758
Gene_locus related to this paper: human-DPP9

Title : A comparative study of the binding properties, dipeptidyl peptidase-4 (DPP-4) inhibitory activity and glucose-lowering efficacy of the DPP-4 inhibitors alogliptin, linagliptin, saxagliptin, sitagliptin and vildagliptin in mice - Berger_2018_Endocrinol.Diabetes.Metab_1_e00002
Author(s) : Berger JP , SinhaRoy R , Pocai A , Kelly TM , Scapin G , Gao YD , Pryor KAD , Wu JK , Eiermann GJ , Xu SS , Zhang X , Tatosian DA , Weber AE , Thornberry NA , Carr RD
Ref : Endocrinol Diabetes Metab , 1 :e00002 , 2018
Abstract : Berger_2018_Endocrinol.Diabetes.Metab_1_e00002
ESTHER : Berger_2018_Endocrinol.Diabetes.Metab_1_e00002
PubMedSearch : Berger_2018_Endocrinol.Diabetes.Metab_1_e00002
PubMedID: 30815539
Gene_locus related to this paper: human-DPP4

Title : Effect of Anagliptin and Sitagliptin on Low-Density Lipoprotein Cholesterol in Type 2 Diabetic Patients with Dyslipidemia and Cardiovascular Risk: Rationale and Study Design of the REASON Trial - Ueda_2018_Cardiovasc.Drugs.Ther_32_73
Author(s) : Ueda S , Shimabukuro M , Arasaki O , Node K , Nomiyama T , Morimoto T
Ref : Cardiovasc Drugs Ther , 32 :73 , 2018
Abstract : Ueda_2018_Cardiovasc.Drugs.Ther_32_73
ESTHER : Ueda_2018_Cardiovasc.Drugs.Ther_32_73
PubMedSearch : Ueda_2018_Cardiovasc.Drugs.Ther_32_73
PubMedID: 29435776

Title : Efficacy and safety of adding evogliptin versus sitagliptin for metformin-treated patients with type 2 diabetes: A 24-week randomized, controlled trial with open label extension - Hong_2017_Diabetes.Obes.Metab_19_654
Author(s) : Hong SM , Park CY , Hwang DM , Han KA , Lee CB , Chung CH , Yoon KH , Mok JO , Park KS , Park SW
Ref : Diabetes Obes Metab , 19 :654 , 2017
Abstract : Hong_2017_Diabetes.Obes.Metab_19_654
ESTHER : Hong_2017_Diabetes.Obes.Metab_19_654
PubMedSearch : Hong_2017_Diabetes.Obes.Metab_19_654
PubMedID: 28058750

Title : Association of Sitagliptin with cardiovascular outcome in diabetic patients: a nationwide cohort study - Yang_2016_Acta.Diabetol_53_461
Author(s) : Yang TY , Liaw YP , Huang JY , Chang HR , Chang KW , Ueng KC
Ref : Acta Diabetologia , 53 :461 , 2016
Abstract : Yang_2016_Acta.Diabetol_53_461
ESTHER : Yang_2016_Acta.Diabetol_53_461
PubMedSearch : Yang_2016_Acta.Diabetol_53_461
PubMedID: 26687195

Title : Anagliptin and sitagliptin as add-ons to metformin for patients with type 2 diabetes: a 24-week, multicentre, randomized, double-blind, active-controlled, phase III clinical trial with a 28-week extension - Jin_2015_Diabetes.Obes.Metab_17_511
Author(s) : Jin SM , Park SW , Yoon KH , Min KW , Song KH , Park KS , Park JY , Park IB , Chung CH , Baik SH , Choi SH , Lee HW , Lee IK , Kim DM , Lee MK
Ref : Diabetes Obes Metab , 17 :511 , 2015
Abstract : Jin_2015_Diabetes.Obes.Metab_17_511
ESTHER : Jin_2015_Diabetes.Obes.Metab_17_511
PubMedSearch : Jin_2015_Diabetes.Obes.Metab_17_511
PubMedID: 25523633

Title : Retrospective and Prospective Human Intravenous and Oral Pharmacokinetic Projection of Dipeptidyl peptidase-IV Inhibitors Using Simple Allometric Principles - Case Studies of ABT-279, ABT-341, Alogliptin, Carmegliptin, Sitagliptin and Vildagliptin - Gilibili_2015_J.Pharm.Pharm.Sci_18_434
Author(s) : Gilibili RR , Bhamidipati RK , Mullangi R , Srinivas NR
Ref : J Pharm Pharm Sci , 18 :434 , 2015
Abstract : Gilibili_2015_J.Pharm.Pharm.Sci_18_434
ESTHER : Gilibili_2015_J.Pharm.Pharm.Sci_18_434
PubMedSearch : Gilibili_2015_J.Pharm.Pharm.Sci_18_434
PubMedID: 26517136

Title : Therapeutic effects of the dipeptidyl peptidase-IV inhibitor, sitagliptin, on non-alcoholic steatohepatitis in FLS-ob\/ob male mice - Onoyama_2015_Mol.Med.Rep_12_6895
Author(s) : Onoyama T , Koda M , Okamoto T , Kishina M , Matono T , Sugihara T , Murawaki Y
Ref : Mol Med Rep , 12 :6895 , 2015
Abstract : Onoyama_2015_Mol.Med.Rep_12_6895
ESTHER : Onoyama_2015_Mol.Med.Rep_12_6895
PubMedSearch : Onoyama_2015_Mol.Med.Rep_12_6895
PubMedID: 26397061

Title : Sitagliptin, a dipeptidyl peptidase-4 inhibitor, improves recognition memory, oxidative stress and hippocampal neurogenesis and upregulates key genes involved in cognitive decline - Gault_2015_Diabetes.Obes.Metab_17_403
Author(s) : Gault VA , Lennox R , Flatt PR
Ref : Diabetes Obes Metab , 17 :403 , 2015
Abstract : Gault_2015_Diabetes.Obes.Metab_17_403
ESTHER : Gault_2015_Diabetes.Obes.Metab_17_403
PubMedSearch : Gault_2015_Diabetes.Obes.Metab_17_403
PubMedID: 25580570

Title : An Inhibitory Antibody against Dipeptidyl Peptidase IV Improves Glucose Tolerance in Vivo - Tang_2013_J.Biol.Chem_288_1307
Author(s) : Tang J , Majeti J , Sudom A , Xiong Y , Lu M , Liu Q , Higbee J , Zhang Y , Wang Y , Wang W , Cao P , Xia Z , Johnstone S , Min X , Yang X , Shao H , Yu T , Sharkov N , Walker N , Tu H , Shen W , Wang Z
Ref : Journal of Biological Chemistry , 288 :1307 , 2013
Abstract : Tang_2013_J.Biol.Chem_288_1307
ESTHER : Tang_2013_J.Biol.Chem_288_1307
PubMedSearch : Tang_2013_J.Biol.Chem_288_1307
PubMedID: 23184939
Gene_locus related to this paper: ratno-dpp4

Title : Dipeptidyl peptidase IV inhibitor sitagliptin reduces local inflammation in adipose tissue and in pancreatic islets of obese mice - Dobrian_2011_Am.J.Physiol.Endocrinol.Metab_300_E410
Author(s) : Dobrian AD , Ma Q , Lindsay JW , Leone KA , Ma K , Coben J , Galkina EV , Nadler JL
Ref : American Journal of Physiology Endocrinol Metab , 300 :E410 , 2011
Abstract : Dobrian_2011_Am.J.Physiol.Endocrinol.Metab_300_E410
ESTHER : Dobrian_2011_Am.J.Physiol.Endocrinol.Metab_300_E410
PubMedSearch : Dobrian_2011_Am.J.Physiol.Endocrinol.Metab_300_E410
PubMedID: 21081706

Title : Evaluation of pharmacokinetic parameters and dipeptidyl peptidase-4 inhibition following single doses of sitagliptin in healthy, young Japanese males - Herman_2011_Br.J.Clin.Pharmacol_71_429
Author(s) : Herman GA , Mistry GC , Yi B , Bergman AJ , Wang AQ , Zeng W , Chen L , Snyder K , Ruckle JL , Larson PJ , Davies MJ , Langdon RB , Gottesdiener KM , Wagner JA
Ref : British Journal of Clinical Pharmacology , 71 :429 , 2011
Abstract : Herman_2011_Br.J.Clin.Pharmacol_71_429
ESTHER : Herman_2011_Br.J.Clin.Pharmacol_71_429
PubMedSearch : Herman_2011_Br.J.Clin.Pharmacol_71_429
PubMedID: 21284702

Title : Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and pioglitazone on glycemic control and measures of beta-cell function in patients with type 2 diabetes - Yoon_2011_Int.J.Clin.Pract_65_154
Author(s) : Yoon KH , Shockey GR , Teng R , Golm GT , Thakkar PR , Meehan AG , Williams-Herman DE , Kaufman KD , Amatruda JM , Steinberg H
Ref : Int J Clin Pract , 65 :154 , 2011
Abstract : Yoon_2011_Int.J.Clin.Pract_65_154
ESTHER : Yoon_2011_Int.J.Clin.Pract_65_154
PubMedSearch : Yoon_2011_Int.J.Clin.Pract_65_154
PubMedID: 21235696

Title : Sitagliptin, a dipeptidyl peptidase-4 inhibitor, does not affect the pharmacokinetics of ethinyl estradiol or norethindrone in healthy female subjects - Migoya_2011_J.Clin.Pharmacol_51_1319
Author(s) : Migoya E , Larson P , Bergman A , Miller J , Johnson-Levonas AO , Lasseter KC , Wagner JA
Ref : Journal of Clinical Pharmacology , 51 :1319 , 2011
Abstract : Migoya_2011_J.Clin.Pharmacol_51_1319
ESTHER : Migoya_2011_J.Clin.Pharmacol_51_1319
PubMedSearch : Migoya_2011_J.Clin.Pharmacol_51_1319
PubMedID: 21209231

Title : Dose-ranging efficacy of sitagliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus - Iwamoto_2010_Endocr.J_57_383
Author(s) : Iwamoto Y , Taniguchi T , Nonaka K , Okamoto T , Okuyama K , Arjona Ferreira JC , Amatruda J
Ref : Endocrine Journal , 57 :383 , 2010
Abstract : Iwamoto_2010_Endocr.J_57_383
ESTHER : Iwamoto_2010_Endocr.J_57_383
PubMedSearch : Iwamoto_2010_Endocr.J_57_383
PubMedID: 20332588

Title : Effects of miglitol, sitagliptin or their combination on plasma glucose, insulin and incretin levels in non-diabetic men - Aoki_2010_Endocr.J_57_667
Author(s) : Aoki K , Masuda K , Miyazaki T , Togashi Y , Terauchi Y
Ref : Endocrine Journal , 57 :667 , 2010
Abstract : Aoki_2010_Endocr.J_57_667
ESTHER : Aoki_2010_Endocr.J_57_667
PubMedSearch : Aoki_2010_Endocr.J_57_667
PubMedID: 20519806

Title : Sitagliptin: a review of its use in the management of type 2 diabetes mellitus - Dhillon_2010_Drugs_70_489
Author(s) : Dhillon S
Ref : Drugs , 70 :489 , 2010
Abstract : Dhillon_2010_Drugs_70_489
ESTHER : Dhillon_2010_Drugs_70_489
PubMedSearch : Dhillon_2010_Drugs_70_489
PubMedID: 20205490

Title : Sitagliptin (MK0431) inhibition of dipeptidyl peptidase IV decreases nonobese diabetic mouse CD4+ T-cell migration through incretin-dependent and -independent pathways - Kim_2010_Diabetes_59_1739
Author(s) : Kim SJ , Nian C , McIntosh CH
Ref : Diabetes , 59 :1739 , 2010
Abstract : Kim_2010_Diabetes_59_1739
ESTHER : Kim_2010_Diabetes_59_1739
PubMedSearch : Kim_2010_Diabetes_59_1739
PubMedID: 20368408

Title : Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes - Williams-Herman_2010_BMC.Endocr.Disord_10_7
Author(s) : Williams-Herman D , Engel SS , Round E , Johnson J , Golm GT , Guo H , Musser BJ , Davies MJ , Kaufman KD , Goldstein BJ
Ref : BMC Endocr Disord , 10 :7 , 2010
Abstract : Williams-Herman_2010_BMC.Endocr.Disord_10_7
ESTHER : Williams-Herman_2010_BMC.Endocr.Disord_10_7
PubMedSearch : Williams-Herman_2010_BMC.Endocr.Disord_10_7
PubMedID: 20412573

Title : Nature of action of Sitagliptin, the dipeptidyl peptidase-IV inhibitor in diabetic animals - Davis_2010_Indian.J.Pharmacol_42_229
Author(s) : Davis JA , Singh S , Sethi S , Roy S , Mittra S , Rayasam G , Bansal V , Sattigeri J , Ray A
Ref : Indian J Pharmacol , 42 :229 , 2010
Abstract : Davis_2010_Indian.J.Pharmacol_42_229
ESTHER : Davis_2010_Indian.J.Pharmacol_42_229
PubMedSearch : Davis_2010_Indian.J.Pharmacol_42_229
PubMedID: 20927248

Title : Effects of vildagliptin twice daily vs. sitagliptin once daily on 24-hour acute glucose fluctuations - Marfella_2010_J.Diabetes.Complications_24_79
Author(s) : Marfella R , Barbieri M , Grella R , Rizzo MR , Nicoletti GF , Paolisso G
Ref : J Diabetes Complications , 24 :79 , 2010
Abstract : Marfella_2010_J.Diabetes.Complications_24_79
ESTHER : Marfella_2010_J.Diabetes.Complications_24_79
PubMedSearch : Marfella_2010_J.Diabetes.Complications_24_79
PubMedID: 19261490

Title : Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis - Engel_2010_Int.J.Clin.Pract_64_984
Author(s) : Engel SS , Williams-Herman DE , Golm GT , Clay RJ , Machotka SV , Kaufman KD , Goldstein BJ
Ref : Int J Clin Pract , 64 :984 , 2010
Abstract : Engel_2010_Int.J.Clin.Pract_64_984
ESTHER : Engel_2010_Int.J.Clin.Pract_64_984
PubMedSearch : Engel_2010_Int.J.Clin.Pract_64_984
PubMedID: 20412332

Title : The effect of DPP-4 inhibition with sitagliptin on incretin secretion and on fasting and postprandial glucose turnover in subjects with impaired fasting glucose - Bock_2010_Clin.Endocrinol.(Oxf)_73_189
Author(s) : Bock G , Dalla Man C , Micheletto F , Basu R , Giesler PD , Laugen J , Deacon CF , Holst JJ , Toffolo G , Cobelli C , Rizza RA , Vella A
Ref : Clinical Endocrinology (Oxf) , 73 :189 , 2010
Abstract : Bock_2010_Clin.Endocrinol.(Oxf)_73_189
ESTHER : Bock_2010_Clin.Endocrinol.(Oxf)_73_189
PubMedSearch : Bock_2010_Clin.Endocrinol.(Oxf)_73_189
PubMedID: 20039889

Title : The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: possible role of stromal-derived factor-1alpha - Fadini_2010_Diabetes.Care_33_1607
Author(s) : Fadini GP , Boscaro E , Albiero M , Menegazzo L , Frison V , de Kreutzenberg S , Agostini C , Tiengo A , Avogaro A
Ref : Diabetes Care , 33 :1607 , 2010
Abstract : Fadini_2010_Diabetes.Care_33_1607
ESTHER : Fadini_2010_Diabetes.Care_33_1607
PubMedSearch : Fadini_2010_Diabetes.Care_33_1607
PubMedID: 20357375

Title : Sitagliptin 100 mg daily effect on DPP-4 inhibition and compound-specific glycemic improvement - Alba_2009_Curr.Med.Res.Opin_25_2507
Author(s) : Alba M , Sheng D , Guan Y , Williams-Herman D , Larson P , Sachs JR , Thornberry N , Herman G , Kaufman KD , Goldstein BJ
Ref : Curr Med Res Opin , 25 :2507 , 2009
Abstract : Alba_2009_Curr.Med.Res.Opin_25_2507
ESTHER : Alba_2009_Curr.Med.Res.Opin_25_2507
PubMedSearch : Alba_2009_Curr.Med.Res.Opin_25_2507
PubMedID: 19691426

Title : Enhancement of hematopoietic stem cell engraftment by inhibition of CXCL12 proteolysis with sitagliptin, an oral dipeptidyl-peptidase IV inhibitor: a report in a case of delayed graft failure -
Author(s) : Focosi D , Kast RE , Metelli MR , Benedetti E , Galimberti S , Papineschi F , Petrini M
Ref : Leuk Res , 33 :178 , 2009
PubMedID: 18513794

Title : Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin--diabetes control and potential adverse events - Ahren_2009_Best.Pract.Res.Clin.Endocrinol.Metab_23_487
Author(s) : Ahren B
Ref : Best Pract Res Clinical Endocrinology Metab , 23 :487 , 2009
Abstract : Ahren_2009_Best.Pract.Res.Clin.Endocrinol.Metab_23_487
ESTHER : Ahren_2009_Best.Pract.Res.Clin.Endocrinol.Metab_23_487
PubMedSearch : Ahren_2009_Best.Pract.Res.Clin.Endocrinol.Metab_23_487
PubMedID: 19748066

Title : Impact of sitagliptin on markers of beta-cell function: a meta-analysis - Riche_2009_Am.J.Med.Sci_337_321
Author(s) : Riche DM , East HE , Riche KD
Ref : American Journal of Medicine Sci , 337 :321 , 2009
Abstract : Riche_2009_Am.J.Med.Sci_337_321
ESTHER : Riche_2009_Am.J.Med.Sci_337_321
PubMedSearch : Riche_2009_Am.J.Med.Sci_337_321
PubMedID: 19322069

Title : Multiple doses of sitagliptin, a selective DPP-4 inhibitor, do not meaningfully alter pharmacokinetics and pharmacodynamics of warfarin - Wright_2009_J.Clin.Pharmacol_49_1157
Author(s) : Wright DH , Herman GA , Maes A , Liu Q , Johnson-Levonas AO , Wagner JA
Ref : Journal of Clinical Pharmacology , 49 :1157 , 2009
Abstract : Wright_2009_J.Clin.Pharmacol_49_1157
ESTHER : Wright_2009_J.Clin.Pharmacol_49_1157
PubMedSearch : Wright_2009_J.Clin.Pharmacol_49_1157
PubMedID: 19783710

Title : Inhibition of DPP-4 with sitagliptin improves glycemic control and restores islet cell mass and function in a rodent model of type 2 diabetes - Mu_2009_Eur.J.Pharmacol_623_148
Author(s) : Mu J , Petrov A , Eiermann GJ , Woods J , Zhou YP , Li Z , Zycband E , Feng Y , Zhu L , Roy RS , Howard AD , Li C , Thornberry NA , Zhang BB
Ref : European Journal of Pharmacology , 623 :148 , 2009
Abstract : Mu_2009_Eur.J.Pharmacol_623_148
ESTHER : Mu_2009_Eur.J.Pharmacol_623_148
PubMedSearch : Mu_2009_Eur.J.Pharmacol_623_148
PubMedID: 19765579

Title : DPP4 inhibitors: from sitagliptin monotherapy to the new alogliptin-pioglitazone combination therapy - Argyrakopoulou_2009_Adv.Ther_26_272
Author(s) : Argyrakopoulou G , Doupis J
Ref : Adv Ther , 26 :272 , 2009
Abstract : Argyrakopoulou_2009_Adv.Ther_26_272
ESTHER : Argyrakopoulou_2009_Adv.Ther_26_272
PubMedSearch : Argyrakopoulou_2009_Adv.Ther_26_272
PubMedID: 19259628

Title : New combination treatments in the management of diabetes: focus on sitagliptin-metformin - Green_2008_Vasc.Health.Risk.Manag_4_743
Author(s) : Green J , Feinglos M
Ref : Vasc Health Risk Manag , 4 :743 , 2008
Abstract : Green_2008_Vasc.Health.Risk.Manag_4_743
ESTHER : Green_2008_Vasc.Health.Risk.Manag_4_743
PubMedSearch : Green_2008_Vasc.Health.Risk.Manag_4_743
PubMedID: 19065992

Title : Sitagliptin augments sympathetic enhancement of the renovascular effects of angiotensin II in genetic hypertension - Jackson_2008_Hypertension_51_1637
Author(s) : Jackson EK , Mi Z
Ref : Hypertension , 51 :1637 , 2008
Abstract : Jackson_2008_Hypertension_51_1637
ESTHER : Jackson_2008_Hypertension_51_1637
PubMedSearch : Jackson_2008_Hypertension_51_1637
PubMedID: 18443229

Title : New treatments for type 2 diabetes mellitus: combined therapy with sitagliptin - Gagliardino_2008_Expert.Opin.Pharmacother_9_1495
Author(s) : Gagliardino JJ , Santoro S , Arellano S , Di Girolamo G
Ref : Expert Opin Pharmacother , 9 :1495 , 2008
Abstract : Gagliardino_2008_Expert.Opin.Pharmacother_9_1495
ESTHER : Gagliardino_2008_Expert.Opin.Pharmacother_9_1495
PubMedSearch : Gagliardino_2008_Expert.Opin.Pharmacother_9_1495
PubMedID: 18518780

Title : Inhibition of dipeptidyl peptidase IV with sitagliptin (MK0431) prolongs islet graft survival in streptozotocin-induced diabetic mice - Kim_2008_Diabetes_57_1331
Author(s) : Kim SJ , Nian C , Doudet DJ , McIntosh CH
Ref : Diabetes , 57 :1331 , 2008
Abstract : Kim_2008_Diabetes_57_1331
ESTHER : Kim_2008_Diabetes_57_1331
PubMedSearch : Kim_2008_Diabetes_57_1331
PubMedID: 18299314

Title : Sitagliptin, an dipeptidyl peptidase-4 inhibitor, does not alter the pharmacokinetics of the sulphonylurea, glyburide, in healthy subjects - Mistry_2008_Br.J.Clin.Pharmacol_66_36
Author(s) : Mistry GC , Bergman AJ , Zheng W , Hreniuk D , Zinny MA , Gottesdiener KM , Wagner JA , Herman GA , Ruddy M
Ref : British Journal of Clinical Pharmacology , 66 :36 , 2008
Abstract : Mistry_2008_Br.J.Clin.Pharmacol_66_36
ESTHER : Mistry_2008_Br.J.Clin.Pharmacol_66_36
PubMedSearch : Mistry_2008_Br.J.Clin.Pharmacol_66_36
PubMedID: 18503607

Title : Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on beta-cell function in patients with type 2 diabetes: a model-based approach - Xu_2008_Diabetes.Obes.Metab_10_1212
Author(s) : Xu L , Man CD , Charbonnel B , Meninger G , Davies MJ , Williams-Herman D , Cobelli C , Stein PP
Ref : Diabetes Obes Metab , 10 :1212 , 2008
Abstract : Xu_2008_Diabetes.Obes.Metab_10_1212
ESTHER : Xu_2008_Diabetes.Obes.Metab_10_1212
PubMedSearch : Xu_2008_Diabetes.Obes.Metab_10_1212
PubMedID: 18476982

Title : Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension - Mistry_2008_J.Clin.Pharmacol_48_592
Author(s) : Mistry GC , Maes AL , Lasseter KC , Davies MJ , Gottesdiener KM , Wagner JA , Herman GA
Ref : Journal of Clinical Pharmacology , 48 :592 , 2008
Abstract : Mistry_2008_J.Clin.Pharmacol_48_592
ESTHER : Mistry_2008_J.Clin.Pharmacol_48_592
PubMedSearch : Mistry_2008_J.Clin.Pharmacol_48_592
PubMedID: 18353996

Title : [Sitagliptin. DPP-4 inhibitors as a useful extension of oral diabetes therapy?] -
Author(s) : Matthes J , Faust M
Ref : Dtsch Med Wochenschr , 133 :2233 , 2008
PubMedID: 18924057

Title : [New drugs\; exenatide and sitagliptin] - van Bronswijk_2008_Ned.Tijdschr.Geneeskd_152_876
Author(s) : van Bronswijk H , Dubois EA , Pijl H , Cohen AF
Ref : Ned Tijdschr Geneeskd , 152 :876 , 2008
Abstract : van Bronswijk_2008_Ned.Tijdschr.Geneeskd_152_876
ESTHER : van Bronswijk_2008_Ned.Tijdschr.Geneeskd_152_876
PubMedSearch : van Bronswijk_2008_Ned.Tijdschr.Geneeskd_152_876
PubMedID: 18512528

Title : Sitagliptin: a novel agent for the management of type 2 diabetes mellitus - Pham_2008_Am.J.Health.Syst.Pharm_65_521
Author(s) : Pham DQ , Nogid A , Plakogiannis R
Ref : Am J Health Syst Pharm , 65 :521 , 2008
Abstract : Pham_2008_Am.J.Health.Syst.Pharm_65_521
ESTHER : Pham_2008_Am.J.Health.Syst.Pharm_65_521
PubMedSearch : Pham_2008_Am.J.Health.Syst.Pharm_65_521
PubMedID: 18319497

Title : Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis - Williams-Herman_2008_BMC.Endocr.Disord_8_14
Author(s) : Williams-Herman D , Round E , Swern AS , Musser B , Davies MJ , Stein PP , Kaufman KD , Amatruda JM
Ref : BMC Endocr Disord , 8 :14 , 2008
Abstract : Williams-Herman_2008_BMC.Endocr.Disord_8_14
ESTHER : Williams-Herman_2008_BMC.Endocr.Disord_8_14
PubMedSearch : Williams-Herman_2008_BMC.Endocr.Disord_8_14
PubMedID: 18954434

Title : Sitagliptin: a novel drug for the treatment of type 2 diabetes - Choy_2007_Cardiol.Rev_15_264
Author(s) : Choy M , Lam S
Ref : Cardiol Rev , 15 :264 , 2007
Abstract : Choy_2007_Cardiol.Rev_15_264
ESTHER : Choy_2007_Cardiol.Rev_15_264
PubMedSearch : Choy_2007_Cardiol.Rev_15_264
PubMedID: 17700385

Title : Transport of the dipeptidyl peptidase-4 inhibitor sitagliptin by human organic anion transporter 3, organic anion transporting polypeptide 4C1, and multidrug resistance P-glycoprotein - Chu_2007_J.Pharmacol.Exp.Ther_321_673
Author(s) : Chu XY , Bleasby K , Yabut J , Cai X , Chan GH , Hafey MJ , Xu S , Bergman AJ , Braun MP , Dean DC , Evers R
Ref : Journal of Pharmacology & Experimental Therapeutics , 321 :673 , 2007
Abstract : Chu_2007_J.Pharmacol.Exp.Ther_321_673
ESTHER : Chu_2007_J.Pharmacol.Exp.Ther_321_673
PubMedSearch : Chu_2007_J.Pharmacol.Exp.Ther_321_673
PubMedID: 17314201

Title : Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin - Hermansen_2007_Diabetes.Obes.Metab_9_733
Author(s) : Hermansen K , Kipnes M , Luo E , Fanurik D , Khatami H , Stein P
Ref : Diabetes Obes Metab , 9 :733 , 2007
Abstract : Hermansen_2007_Diabetes.Obes.Metab_9_733
ESTHER : Hermansen_2007_Diabetes.Obes.Metab_9_733
PubMedSearch : Hermansen_2007_Diabetes.Obes.Metab_9_733
PubMedID: 17593236

Title : Disposition of the dipeptidyl peptidase 4 inhibitor sitagliptin in rats and dogs - Beconi_2007_Drug.Metab.Dispos_35_525
Author(s) : Beconi MG , Reed JR , Teffera Y , Xia YQ , Kochansky CJ , Liu DQ , Xu S , Elmore CS , Ciccotto S , Hora DF , Stearns RA , Vincent SH
Ref : Drug Metabolism & Disposition: The Biological Fate of Chemicals , 35 :525 , 2007
Abstract : Beconi_2007_Drug.Metab.Dispos_35_525
ESTHER : Beconi_2007_Drug.Metab.Dispos_35_525
PubMedSearch : Beconi_2007_Drug.Metab.Dispos_35_525
PubMedID: 17220241

Title : Dipeptidyl peptidase 4 inhibition with sitagliptin: a new therapy for type 2 diabetes - Deacon_2007_Expert.Opin.Investig.Drugs_16_533
Author(s) : Deacon CF
Ref : Expert Opin Investig Drugs , 16 :533 , 2007
Abstract : Deacon_2007_Expert.Opin.Investig.Drugs_16_533
ESTHER : Deacon_2007_Expert.Opin.Investig.Drugs_16_533
PubMedSearch : Deacon_2007_Expert.Opin.Investig.Drugs_16_533
PubMedID: 17371200

Title : Sitagliptin: Profile of a novel DPP-4 inhibitor for the treatment of type 2 diabetes - Gallwitz_2007_Drugs.Today.(Barc)_43_13
Author(s) : Gallwitz B
Ref : Drugs Today (Barc) , 43 :13 , 2007
Abstract : Gallwitz_2007_Drugs.Today.(Barc)_43_13
ESTHER : Gallwitz_2007_Drugs.Today.(Barc)_43_13
PubMedSearch : Gallwitz_2007_Drugs.Today.(Barc)_43_13
PubMedID: 17315049

Title : Triazolopiperazine-amides as dipeptidyl peptidase IV inhibitors: close analogs of JANUVIA (sitagliptin phosphate) - Kim_2007_Bioorg.Med.Chem.Lett_17_3373
Author(s) : Kim D , Kowalchick JE , Edmondson SD , Mastracchio A , Xu J , Eiermann GJ , Leiting B , Wu JK , Pryor KD , Patel RA , He H , Lyons KA , Thornberry NA , Weber AE
Ref : Bioorganic & Medicinal Chemistry Lett , 17 :3373 , 2007
Abstract : Kim_2007_Bioorg.Med.Chem.Lett_17_3373
ESTHER : Kim_2007_Bioorg.Med.Chem.Lett_17_3373
PubMedSearch : Kim_2007_Bioorg.Med.Chem.Lett_17_3373
PubMedID: 17434732

Title : Sitagliptin with metformin: profile of a combination for the treatment of type 2 diabetes - Gallwitz_2007_Drugs.Today.(Barc)_43_681
Author(s) : Gallwitz B
Ref : Drugs Today (Barc) , 43 :681 , 2007
Abstract : Gallwitz_2007_Drugs.Today.(Barc)_43_681
ESTHER : Gallwitz_2007_Drugs.Today.(Barc)_43_681
PubMedSearch : Gallwitz_2007_Drugs.Today.(Barc)_43_681
PubMedID: 17987221

Title : Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: focus on sitagliptin - Herman_2007_Clin.Pharmacol.Ther_81_761
Author(s) : Herman GA , Stein PP , Thornberry NA , Wagner JA
Ref : Clinical Pharmacology & Therapeutics , 81 :761 , 2007
Abstract : Herman_2007_Clin.Pharmacol.Ther_81_761
ESTHER : Herman_2007_Clin.Pharmacol.Ther_81_761
PubMedSearch : Herman_2007_Clin.Pharmacol.Ther_81_761
PubMedID: 17392725

Title : Sitagliptin: profile of a novel DPP-4 inhibitor for the treatment of type 2 diabetes (update) - Gallwitz_2007_Drugs.Today.(Barc)_43_801
Author(s) : Gallwitz B
Ref : Drugs Today (Barc) , 43 :801 , 2007
Abstract : Gallwitz_2007_Drugs.Today.(Barc)_43_801
ESTHER : Gallwitz_2007_Drugs.Today.(Barc)_43_801
PubMedSearch : Gallwitz_2007_Drugs.Today.(Barc)_43_801
PubMedID: 18174966

Title : Multiple-dose administration of sitagliptin, a dipeptidyl peptidase-4 inhibitor, does not alter the single-dose pharmacokinetics of rosiglitazone in healthy subjects - Mistry_2007_J.Clin.Pharmacol_47_159
Author(s) : Mistry GC , Bergman AJ , Luo WL , Cilissen C , Haazen W , Davies MJ , Gottesdiener KM , Wagner JA , Herman GA
Ref : Journal of Clinical Pharmacology , 47 :159 , 2007
Abstract : Mistry_2007_J.Clin.Pharmacol_47_159
ESTHER : Mistry_2007_J.Clin.Pharmacol_47_159
PubMedSearch : Mistry_2007_J.Clin.Pharmacol_47_159
PubMedID: 17244766

Title : Effect of a single cyclosporine dose on the single-dose pharmacokinetics of sitagliptin (MK-0431), a dipeptidyl peptidase-4 inhibitor, in healthy male subjects - Krishna_2007_J.Clin.Pharmacol_47_165
Author(s) : Krishna R , Bergman A , Larson P , Cote J , Lasseter K , Dilzer S , Wang A , Zeng W , Chen L , Wagner J , Herman G
Ref : Journal of Clinical Pharmacology , 47 :165 , 2007
Abstract : Krishna_2007_J.Clin.Pharmacol_47_165
ESTHER : Krishna_2007_J.Clin.Pharmacol_47_165
PubMedSearch : Krishna_2007_J.Clin.Pharmacol_47_165
PubMedID: 17244767

Title : Characterization of two cyclic metabolites of sitagliptin - Liu_2007_Drug.Metab.Dispos_35_521
Author(s) : Liu DQ , Arison BH , Stearns RA , Kim D , Vincent SH
Ref : Drug Metabolism & Disposition: The Biological Fate of Chemicals , 35 :521 , 2007
Abstract : Liu_2007_Drug.Metab.Dispos_35_521
ESTHER : Liu_2007_Drug.Metab.Dispos_35_521
PubMedSearch : Liu_2007_Drug.Metab.Dispos_35_521
PubMedID: 17220240

Title : Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes - Scott_2007_Int.J.Clin.Pract_61_171
Author(s) : Scott R , Wu M , Sanchez M , Stein P
Ref : Int J Clin Pract , 61 :171 , 2007
Abstract : Scott_2007_Int.J.Clin.Pract_61_171
ESTHER : Scott_2007_Int.J.Clin.Pract_61_171
PubMedSearch : Scott_2007_Int.J.Clin.Pract_61_171
PubMedID: 17156104

Title : Sitagliptin - Lyseng-Williamson_2007_Drugs_67_587
Author(s) : Lyseng-Williamson KA
Ref : Drugs , 67 :587 , 2007
Abstract : Lyseng-Williamson_2007_Drugs_67_587
ESTHER : Lyseng-Williamson_2007_Drugs_67_587
PubMedSearch : Lyseng-Williamson_2007_Drugs_67_587
PubMedID: 17352516

Title : Sitagliptin phosphate: a DPP-4 inhibitor for the treatment of type 2 diabetes mellitus - Zerilli_2007_Clin.Ther_29_2614
Author(s) : Zerilli T , Pyon EY
Ref : Clin Ther , 29 :2614 , 2007
Abstract : Zerilli_2007_Clin.Ther_29_2614
ESTHER : Zerilli_2007_Clin.Ther_29_2614
PubMedSearch : Zerilli_2007_Clin.Ther_29_2614
PubMedID: 18201579

Title : Discovery of JANUVIA (Sitagliptin), a selective dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes - Thornberry_2007_Curr.Top.Med.Chem_7_557
Author(s) : Thornberry NA , Weber AE
Ref : Curr Top Med Chem , 7 :557 , 2007
Abstract : Thornberry_2007_Curr.Top.Med.Chem_7_557
ESTHER : Thornberry_2007_Curr.Top.Med.Chem_7_557
PubMedSearch : Thornberry_2007_Curr.Top.Med.Chem_7_557
PubMedID: 17352677

Title : Rational design of a novel, potent, and orally bioavailable cyclohexylamine DPP-4 inhibitor by application of molecular modeling and X-ray crystallography of sitagliptin - Biftu_2007_Bioorg.Med.Chem.Lett_17_3384
Author(s) : Biftu T , Scapin G , Singh S , Feng D , Becker JW , Eiermann G , He H , Lyons K , Patel S , Petrov A , Sinha-Roy R , Zhang B , Wu J , Zhang X , Doss GA , Thornberry NA , Weber AE
Ref : Bioorganic & Medicinal Chemistry Lett , 17 :3384 , 2007
Abstract : Biftu_2007_Bioorg.Med.Chem.Lett_17_3384
ESTHER : Biftu_2007_Bioorg.Med.Chem.Lett_17_3384
PubMedSearch : Biftu_2007_Bioorg.Med.Chem.Lett_17_3384
PubMedID: 17433672
Gene_locus related to this paper: human-DPP4

Title : [Incretin strategy in the treatment of type 2 diabetes mellitus--the DPP-IV inhibitor sitagliptin] - Perusicova_2007_Vnitr.Lek_53_1109
Author(s) : Perusicova J
Ref : Vnitr Lek , 53 :1109 , 2007
Abstract : Perusicova_2007_Vnitr.Lek_53_1109
ESTHER : Perusicova_2007_Vnitr.Lek_53_1109
PubMedSearch : Perusicova_2007_Vnitr.Lek_53_1109
PubMedID: 18072437

Title : Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor -
Author(s) : Bergman AJ , Cote J , Yi B , Marbury T , Swan SK , Smith W , Gottesdiener K , Wagner J , Herman GA
Ref : Diabetes Care , 30 :1862 , 2007
PubMedID: 17468348

Title : Sitagliptin -
Author(s) : Drucker D , Easley C , Kirkpatrick P
Ref : Nat Rev Drug Discov , 6 :109 , 2007
PubMedID: 17342863

Title : Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes - Goldstein_2007_Diabetes.Care_30_1979
Author(s) : Goldstein BJ , Feinglos MN , Lunceford JK , Johnson J , Williams-Herman DE
Ref : Diabetes Care , 30 :1979 , 2007
Abstract : Goldstein_2007_Diabetes.Care_30_1979
ESTHER : Goldstein_2007_Diabetes.Care_30_1979
PubMedSearch : Goldstein_2007_Diabetes.Care_30_1979
PubMedID: 17485570

Title : Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when co-administered in patients with type 2 diabetes - Herman_2006_Curr.Med.Res.Opin_22_1939
Author(s) : Herman GA , Bergman A , Yi B , Kipnes M
Ref : Curr Med Res Opin , 22 :1939 , 2006
Abstract : Herman_2006_Curr.Med.Res.Opin_22_1939
ESTHER : Herman_2006_Curr.Med.Res.Opin_22_1939
PubMedSearch : Herman_2006_Curr.Med.Res.Opin_22_1939
PubMedID: 17022853

Title : Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers - Bergman_2006_Clin.Ther_28_55
Author(s) : Bergman AJ , Stevens C , Zhou Y , Yi B , Laethem M , De Smet M , Snyder K , Hilliard D , Tanaka W , Zeng W , Tanen M , Wang AQ , Chen L , Winchell G , Davies MJ , Ramael S , Wagner JA , Herman GA
Ref : Clin Ther , 28 :55 , 2006
Abstract : Bergman_2006_Clin.Ther_28_55
ESTHER : Bergman_2006_Clin.Ther_28_55
PubMedSearch : Bergman_2006_Clin.Ther_28_55
PubMedID: 16490580

Title : Sitagliptin: a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes - Miller_2006_Ann.Pharmacother_40_1336
Author(s) : Miller S , St Onge EL
Ref : Annals of Pharmacotherapy , 40 :1336 , 2006
Abstract : Miller_2006_Ann.Pharmacother_40_1336
ESTHER : Miller_2006_Ann.Pharmacother_40_1336
PubMedSearch : Miller_2006_Ann.Pharmacother_40_1336
PubMedID: 16868220

Title : Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus - Raz_2006_Diabetologia_49_2564
Author(s) : Raz I , Hanefeld M , Xu L , Caria C , Williams-Herman D , Khatami H
Ref : Diabetologia , 49 :2564 , 2006
Abstract : Raz_2006_Diabetologia_49_2564
ESTHER : Raz_2006_Diabetologia_49_2564
PubMedSearch : Raz_2006_Diabetologia_49_2564
PubMedID: 17001471

Title : Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study - Rosenstock_2006_Clin.Ther_28_1556
Author(s) : Rosenstock J , Brazg R , Andryuk PJ , Lu K , Stein P
Ref : Clin Ther , 28 :1556 , 2006
Abstract : Rosenstock_2006_Clin.Ther_28_1556
ESTHER : Rosenstock_2006_Clin.Ther_28_1556
PubMedSearch : Rosenstock_2006_Clin.Ther_28_1556
PubMedID: 17157112

Title : Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes - Mu_2006_Diabetes_55_1695
Author(s) : Mu J , Woods J , Zhou YP , Roy RS , Li Z , Zycband E , Feng Y , Zhu L , Li C , Howard AD , Moller DE , Thornberry NA , Zhang BB
Ref : Diabetes , 55 :1695 , 2006
Abstract : Mu_2006_Diabetes_55_1695
ESTHER : Mu_2006_Diabetes_55_1695
PubMedSearch : Mu_2006_Diabetes_55_1695
PubMedID: 16731832

Title : Pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects - Herman_2006_J.Clin.Pharmacol_46_876
Author(s) : Herman GA , Bergman A , Liu F , Stevens C , Wang AQ , Zeng W , Chen L , Snyder K , Hilliard D , Tanen M , Tanaka W , Meehan AG , Lasseter K , Dilzer S , Blum R , Wagner JA
Ref : Journal of Clinical Pharmacology , 46 :876 , 2006
Abstract : Herman_2006_J.Clin.Pharmacol_46_876
ESTHER : Herman_2006_J.Clin.Pharmacol_46_876
PubMedSearch : Herman_2006_J.Clin.Pharmacol_46_876
PubMedID: 16855072

Title : Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes - Herman_2006_J.Clin.Endocrinol.Metab_91_4612
Author(s) : Herman GA , Bergman A , Stevens C , Kotey P , Yi B , Zhao P , Dietrich B , Golor G , Schrodter A , Keymeulen B , Lasseter KC , Kipnes MS , Snyder K , Hilliard D , Tanen M , Cilissen C , De Smet M , De Lepeleire I , Van Dyck K , Wang AQ , Zeng W , Davies MJ , Tanaka W , Holst JJ , Deacon CF , Gottesdiener KM , Wagner JA
Ref : J Clinical Endocrinology Metab , 91 :4612 , 2006
Abstract : Herman_2006_J.Clin.Endocrinol.Metab_91_4612
ESTHER : Herman_2006_J.Clin.Endocrinol.Metab_91_4612
PubMedSearch : Herman_2006_J.Clin.Endocrinol.Metab_91_4612
PubMedID: 16912128

Title : (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)- yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes - Kim_2005_J.Med.Chem_48_141
Author(s) : Kim D , Wang L , Beconi M , Eiermann GJ , Fisher MH , He H , Hickey GJ , Kowalchick JE , Leiting B , Lyons K , Marsilio F , McCann ME , Patel RA , Petrov A , Scapin G , Patel SB , Roy RS , Wu JK , Wyvratt MJ , Zhang BB , Zhu L , Thornberry NA , Weber AE
Ref : Journal of Medicinal Chemistry , 48 :141 , 2005
Abstract : Kim_2005_J.Med.Chem_48_141
ESTHER : Kim_2005_J.Med.Chem_48_141
PubMedSearch : Kim_2005_J.Med.Chem_48_141
PubMedID: 15634008
Gene_locus related to this paper: human-DPP4